Invivyd Reports 22% Revenue Growth but Faces Rising R&D Costs Amid VYD2311 Trial Progress

Event summary

  • Q1 2026 revenue from PEMGARDA increased 22% YoY to $13.7M, but R&D expenses surged to $30.7M due to DECLARATION trial costs.
  • DECLARATION trial enrollment completed in March 2026, with top-line data now expected in Q3 2026 after study upsizing.
  • IDMC recommended reducing post-dose monitoring time for VYD2311 from 2 hours to 30 minutes, expanding eligibility criteria.
  • Invivyd raised ~$20M in April 2026 via ATM offering, ending Q1 with $184.2M in cash.
  • Company advanced measles (VMS063) and RSV (VBY329) antibody candidates toward IND readiness.

The big picture

Invivyd's Q1 results highlight the tension between commercial momentum for PEMGARDA and the financial burden of advancing VYD2311 through pivotal trials. The company's strategic focus on monoclonal antibodies as an alternative to vaccines positions it in a growing niche, but success hinges on demonstrating superior efficacy and safety profiles against established competitors. With $184M in cash and expanding pipeline candidates, Invivyd has runway to execute, but investors will scrutinize operational efficiency as clinical milestones approach.

What we're watching

Trial Timing
Whether the two-month delay in DECLARATION data readout will impact VYD2311's commercialization timeline.
Cost Control
How Invivyd manages rising R&D expenses as it prepares for potential VYD2311 launch.
Competitive Positioning
The pace at which Invivyd can differentiate VYD2311 from mRNA vaccines in safety and tolerability.